Epkinly (epcoritamab-bysp)

P1, N=12, Not yet recruiting, University of Utah

P1/2, N=28, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | N=14 --> 28

P3, N=379, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

P2, N=0, Withdrawn, Memorial Sloan Kettering Cancer Center | N=27 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026

P2/3, N=57, Not yet recruiting, University Of Cologne

However, epcoritamab induced a rapid systemic response along with partial neurological improvement. This case highlights the potential role of bispecific antibody therapy in refractory DLBCL with CNS involvement, an area of significant unmet clinical need.

P2/3, N=41, Not yet recruiting, University Of Cologne

Chemoimmunotherapy for malignant lymphoma, including corticosteroids, rituximab (R), and Bruton's tyrosine kinase inhibitors, depletes normal lymphocytes and disrupts lymphocyte function...We treated a case of relapsed malignant lymphoma, infected with triple infections, Campylobacter coli, Cytomegalovirus, and SARS-CoV-2, during treatment with epcoritamab after standard chemoimmunotherapies, including R-cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), and R-bendamustine...His treatment for infections included remdesivir, meropenem, and ganciclovir...Epcoritamab can demonstrate long-standing B-cell depletion; however, a long-term influence on T cells is still elusive. This case suggested that we should pay special attention to patients with B-cell manipulating therapy including R, CAR-T, and BiTEs such as epcoritamab.

P2, N=20, Recruiting, Gottfried von Keudell, MD PhD | Trial primary completion date: Oct 2025 --> Apr 2027

P1/2, N=14, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

P2, N=10, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez

This review examines CD20 × CD3 bispecific antibodies (BsAbs) like mosunetuzumab, epcoritamab, odronextamab, and glofitamab, which link malignant B-cells and T-cells, thus inducing targeted tumor lysis...This review details their mechanisms, grading, and management, including the use of tocilizumab and corticosteroids...Expert recommendations for antimicrobial prophylaxis, including herpes and varicella zoster virus, pneumocystis, and immunoglobulin supplements are crucial for mitigating these risks. While BsAbs offer an "off-the-shelf" advantage, balancing their efficacy with comprehensive toxicity management is crucial for maximizing patient outcomes.